Phacilitate Leaders Forum

The Evolution of Advanced Therapies

The Evolution of Advanced Therapies

Advanced therapies is one of the most innovative industries of our time. How do we continue to adapt and evolve for sustainable success?

Successful evolution depends on the ability to adapt and thrive in changing conditions. Over time, incremental changes provide a competitive advantage. 

Whether from payers, patients or physicians, we need to survive the oncoming pressures facing our industry.

So ask yourself, if 2017 was ‘the year everything happened’, how will advanced therapies continue to evolve? Not just for the next 12 months but for the next 30 years?

 


 

 

We think three of the biggest pressures facing us are:

  1. Cost per patient. How do we go from $500,000 per patient to $30,000 per patient?
  2. Payer acceptance. How will payers evaluate my product against the current standard of care?   
  3. Lack of knowledge. One of the biggest innovation killers in our industry.

How will better cost of goods, pricing models and open collaboration impact the evolution of ATMPs to drive commercial success?


 

Phacilitate has grown in step with the industry since 2005 and we care about what happens next.

You told us what your challenges are and you can find solutions to each and every one at Phacilitate Leaders Europe this September. Check out the agenda at a glance here!

Testimonials
  • Real thinking forward combining experts in the field from manufacturing, regulatory and value vision” – “great network with strong experience and sharing risks & opportunities
    Jean-Philippe Combal
    GenSight Biologics
  • The conference consistently proves to be a great forum for networking with industry leaders in the development of cellular and gene therapies as well as vendors for important technologies and services.
    Michael Covington
    Juno Therapeutics, Inc
  • It was a very interesting event as all participants, including speakers were ready to exchange, even on the most challenging subjects such as reimbursement, GMP guidance
    Bertrand Alexandre
    Celyad
  • Phacilitate EU delivered it's promise and more, the topics discussed were highly relevant, with very good and professional speakers and panelists. You will see me next year in Berlin.
    Dr Ohad Karnieli
    Karnieli Ltd